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Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however,
available studies have shown inconsistent results. In this study, embedded within the population-based
Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes. Adjusted
means were calculated for subclinical atherosclerosis using general linear models. Using Cox regression, the
hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated. A total of 262
psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.
Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body
mass index levels. The adjusted carotid intima–media thickness was 1.02±0.18mm for psoriasis and
1.02±0.16mm for reference subjects. Similarly, crude and adjusted ankle–brachial index, pulse-wave velocity,
and coronary artery calcium scores did not differ between the two groups. The risk of incident CVD was not
increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50–1.06). The results were similar
when coronary heart disease, stroke, and heart failure were analyzed separately. Psoriasis patients with
predominantly mild disease from the general population are as likely to develop atherosclerosis and
cardiovascular events as subjects without psoriasis.
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INTRODUCTION
Psoriasis is an inflammatory condition affecting the skin and,
in B10% of the patients, the joints (Gelfand et al., 2005;
Nestle et al., 2009). In the past decade, most observational
studies on psoriasis have suggested that the chronic
inflammation in psoriasis is more than skin deep and
results in a ‘‘psoriatic march’’ that can lead to endothelial
dysfunction, atherosclerosis, and eventually to cardiovascular
disease (CVD) (Boehncke et al., 2010). Case–control studies
assessing the association between psoriasis and atherosclerosis
are often based on patients from tertiary clinics with more
severe and recalcitrant disease and a higher degree of
impairment, and are therefore not necessarily representative
of the general psoriasis population (Naldi et al., 2005; Gisondi
et al., 2007; Balci et al., 2009). Studies based on routine
databases or selected groups have shown an elevated risk
of myocardial infarction (MI) in a specific subgroup, namely
young psoriasis patients treated with systemic medication
(Gelfand et al., 2006; Brauchli et al., 2009; Ahlehoff et al.,
2011a; Li et al., 2012). Emerging research on CVD in psoriasis
in large population-based cohorts using research and routine
databases report inconsistent results (Mallbris et al., 2004;
Gelfand et al., 2006; Kaye et al., 2008; Kimball et al., 2008;
Brauchli et al., 2009; Gelfand et al., 2009; Prodanovich et al.,
2009; Wakkee et al., 2009; Kimball et al., 2010; Mehta et al.,
2010; Schmitt and Ford, 2010; Wakkee et al., 2010; Stern and
Huibregtse, 2011; Yang et al., 2011; Ahlehoff et al., 2011a,
2011b; Armstrong et al., 2012; Chiang et al., 2012; Li et al.,
2012; Maradit-Kremers et al., 2012; Shapiro et al., 2012).
Differences across studies can be explained by discrepancies
in case ascertainment and definition of exposure and
outcome, study setting and design, adjustment for cardio-
vascular risk factors, inadequate statistical power, and residual
confounding.
There is no population-based study thus far in which all
subjects receive the same examinations independent of their
health status, focussing simultaneously on atherosclerosis and
hard cardiovascular outcomes, adjusting for several risk
factors. Therefore, the present study was designed to address
subclinical atherosclerosis, coronary heart disease (CHD),
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stroke, and heart failure in subjects diagnosed with psoriasis
by a physician, and reference subjects in the population-based
Rotterdam Study, where detailed information on cardiovascu-
lar risk factors is available (Hofman et al., 2011).
RESULTS
A total of 262 psoriasis patients and 8,009 reference subjects
were followed up for a median (interquartile range) of
11.1 (8.2–16.5) and 9.1 (7.5–16.0) years, respectively. Of
the 262 psoriasis patients, 114 patients (44%) were diagnosed
by the dermatologist, 5 (2%) by the rheumatologist, 32% by
the general practitioner (GP), 16% based on antipsoriatic
medication, and 6% were diagnosed with psoriasis during
skin examination. The gender distribution was comparable in
both groups, but the psoriasis subjects were slightly younger
(Po0.001) (Table 1). Almost a quarter of patients had received
systemic medication or UV therapy. At study entry, psoriasis
patients smoked significantly more (32 vs. 22%), had a slightly
higher body mass index (BMI)(27.1 vs. 26.5 kg/m2) and
diastolic blood pressure, and used more cholesterol-lowering
medication. There were no significant differences in total and
high-density lipoprotein cholesterol, systolic blood pressure,
antihypertensive treatment, or diabetes mellitus between the
two groups (Table 1).
Subclinical measures of atherosclerosis
The crude mean carotid intima–media thickness (IMT) for
psoriasis was 1.00±0.20 mm and 1.02±0.21 mm for refer-
ence subjects (P¼0.47; Table 2). Neither adjusting for age
and gender alone nor adjusting for all cardiovascular risk
factors at the time of the IMT measurement changed the mean
IMT considerably for the two groups (fully adjusted mean
1.02±0.18 mm for psoriasis and 1.02±0.16 mm for the
reference population, P¼ 0.62). Of the psoriasis patients,
72% had a carotid plaque compared with 65% of the
reference population (P¼ 0.09). When adjusting for age,
gender, and cardiovascular risk factors, psoriasis patients had
9% more plaques than the reference population (P¼ 0.01).
The mean ankle–brachial index (ABI) was not significantly
different, with a fully adjusted mean of 1.04±0.18 for
psoriasis and 1.05±0.17 for reference subjects. There was
no significant difference in the presence of peripheral artery
disease between the two groups (P¼ 0.26).
The crude geometric mean coronary artery calcium (CAC)
score was 53.51 (95% confidence interval (95% confidence
interval (CI)) 32.99–86.42) in psoriasis compared with
55.98 (95% CI 51.26–61.12) in the reference group (P¼0.86).
The adjusted CAC scores did not change considerably, and the
difference between the two cohorts remained nonsignificant.
Carotid–femoral pulse-wave velocity (PWV) was also not
significantly different in the crude and fully adjusted models,
with an adjusted PWV of 13.49±2.60 m s1 for psoriasis and
13.20±2.56 m s 1 for the reference population (Table 2).
Cardiovascular disease
We followed up 259 psoriasis patients and 7,931 reference
subjects for incident cardiovascular events. There were a total
of 1,613 cardiovascular events during more than 89,000
person-years of follow-up, of which 28 occurred among
psoriasis patients. The crude hazard ratio (HR) for psoriasis
in developing the composite outcome CVD, treating psoriasis
as a time-dependent variable, was borderline significant with
a HR of 0.69 (95% CI 0.48–1.00), suggesting that psoriasis was
protective for CVD. However, after adjusting for age and
gender, the association was no longer significant (HR 0.83,
95% CI 0.57–1.21), and this was comparable to the fully
adjusted HR of 0.73 (95% CI 0.50–1.06). When separating
CVD into its components, the crude risk for incident CHD was
not significantly different in psoriasis patients and reference
subjects (HR 0.69, 95% CI 0.40–1.16), and remained similar
after adjusting for age and gender and cardiovascular risk
factors (Table 3). The fully adjusted risk of developing incident
cerebral infarction was not significantly elevated in psoriasis
(HR 0.69, 95% CI 0.36–1.34) nor was the risk for incident
heart failure (HR 0.80, 95% CI 0.51–1.25).
Table 1. Characteristics of psoriasis patients and
reference population in the Rotterdam Study
Variable
Psoriasis
N¼262
Reference
N¼ 8,009 P-valuea
Age 64.32±6.82 68.78±9.47 o0.001
Male, n (%) 115 (43.9) 3377 (42.2) 0.56
Psoriasis therapyb
Topical therapy only, n (%) 158 (56.1) NA
UV therapy, n (%) 31 (14.8) NA
Systemic therapy, n (%) 46 (17.6) NA
No therapy, n (%) 52 (19.8) NA
Systolic blood pressure,
mm Hg
141±21.92 140.7±22.2 0.85
Diastolic blood pressure,
mm Hg
76.7±10.6 75.2±11.8 0.05
Antihypertensive treatment,
n (%)
85 (32.4) 2515 (31.4) 0.72
Hypertension, n (%)c 157 (59.9) 5036 (62.9) 0.33
Body mass index, kg m2 27.1±3.9 26.5±3.8 0.007
Waist-to-hip ratio 0.91±0.08 0.91±0.09 0.32
Total cholesterol, mmol l 1 6.27±1.24 6.37±1.21 0.20
HDL cholesterol, mmol l1 1.34±0.35 1.35±0.36 0.63
Cholesterol-lowering
medication, n (%)
23 (8.8) 403 (5.0) 0.007
Diabetes mellitus, n (%) 18 (6.9) 698 (8.7) 0.30
Current smoking, n (%) 85 (32.4) 1773 (22.1) o0.001
Abbreviations: HDL, high-density lipoprotein; mmol l 1, millimole per
liter.
Data are mean±SD for continuous variables and proportions for dichot-
omous variables.
aP-values were calculated with the t-test for continuous variables and with
the w2 test for proportions.
bPercentages do not add up to 100% because some patients had UV and
systemic therapy.
cHypertension: blood pressure Z140/90 and/or antihypertensive
medication.
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Sensitivity analysis
For subclinical measures of atherosclerosis, the subgroup
analyses in mild psoriasis patients and in those with moderate
to severe disease, each compared with the reference subjects,
showed no significant difference between the groups (data not
shown). Patients with mild psoriasis (n¼ 197), representing
76% of the psoriasis cohort, showed no elevated adjusted risk
of developing CHD (HR 0.85, 95% CI 0.49–1.47), cerebral
infarction (HR 0.62, 95% CI 0.28–1.38), or heart failure
(HR 1.01, 95% CI 0.64–1.59). The 62 patients with moderate
to severe psoriasis had a fully adjusted HR for CHD of 0.21
(95% CI 0.03–1.50). The significantly decreased risk of
heart failure of 0.12 (95% CI 0.02–0.83) and CVD of 0.37
(95% CI 0.15–0.89) for the subgroup of moderate to severe
psoriasis was no longer significant after adjusting for age and
gender (Table 3).
The fully adjusted risk of developing CVD was not
elevated in patients with prevalent psoriasis at inclusion to
the study compared with incident psoriasis cases and refer-
ence subjects (HR 0.64, 95% CI 0.37–1.10), indicating
that patients with a longer duration of psoriatic disease in
our study did not have an increased risk of developing a
cardiovascular event.
DISCUSSION
The present prospective population-based study with more
than 10 years of follow-up showed a similar risk factor profile
for CVD among subjects with psoriasis compared with those
without psoriasis. Extensively examined psoriasis patients
diagnosed by the dermatologist or the GP were not at a higher
risk for subclinical atherosclerosis compared with the refer-
ence population, and psoriasis was not an independent risk
factor for incident cardiovascular events.
Subclinical measures of atherosclerosis
AmongB140 psoriasis cases, none of the adjusted subclinical
measures of atherosclerosis were higher compared with the
reference population, with the exception of the binary out-
come carotid plaque, which was significantly elevated in
psoriasis after adjustment. Carotid plaques could be actually
increased in psoriasis patients compared with controls.
However, other reasons are likely to explain this finding.
Because of the number of tests in our study (n¼ 8), chance
findings owing to multiple testing may occur: the P-value for
the fully adjusted model for plaque exceeded the Bonferroni-
corrected P-value of 0.006 (0.05/8). Furthermore, using a
dichotomous variable might have affected our findings;
Table 2. Subclinical measures of atherosclerosis in psoriasis patients after psoriasis diagnosis, compared with the
reference population
Measure of atherosclerosis N Crude mean±SDa P-value
Age- and gender-adjusted
mean±SDa P-value
Fully adjusted
mean±SDab P-value
Carotid intima–media thickness, mm
Psoriasis 143 1.00±0.20 0.47 1.03±0.19 0.49 1.02±0.18 0.62
Reference 6,525 1.02±0.21 1.02±0.16 1.02±0.16
Carotid plaque, %
Psoriasis 165 71.5% 0.09 75.5% 0.004 73.9% 0.01
Reference 6,519 65.1% 65.0% 65.0%
Ankle–brachial index
Psoriasis 139 1.06±0.17 0.40 1.03±0.19 0.21 1.04±0.18 0.51
Reference 7,022 1.04±0.20 1.05±0.17 1.05±0.17
Peripheral artery disease, %c
Psoriasis 139 14.4% 0.26 20.1% 0.48 19.0% 0.73
Reference 7,022 18.1% 18.0% 18.0%
CAC scored
Psoriasis 106 53.51 (32.99–86.42) 0.86 59.64 (38.50–92.04) 0.77 51.40 (33.59–78.41) 0.69
Reference 3,168 55.98 (51.26–61.12) 55.77 (51.50–60.41) 56.05 (51.89–60.55)
Pulse-wave velocity, m s1
Psoriasis 117 13.39±3.14 0.54 13.61±2.81 0.11 13.49±2.60 0.24
Reference 4,551 13.21±3.17 13.20±2.77 13.20±2.56
Abbreviations: CAC score, coronary artery calcium score; CI, confidence interval.
aMeans are estimated marginal means using general linear model analysis of variance.
bAdjusted for age, gender, current smoking, body mass index, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, antihypertensive
medication, and diabetes mellitus.
cPeripheral artery disease was defined as ankle–brachial index values of 0.9 or less.
dCAC score data were log transformed; we present back-transformed geometric means and 95% CIs.
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when IMT was used as a continuous variable, no significant
difference was seen between the two groups. Our findings are
in line with a study observing no difference in endothelial
dysfunction between psoriasis patients and healthy controls
after exclusion of CVD and traditional cardiovascular risk
factors (Martyn-Simmons et al., 2011). Other studies analyzing
IMT, ABI, CAC, and PWV in psoriasis patients compared with
controls are few, are relatively small case–control studies with
a suboptimal selection of controls, and are conducted in
selected groups such as patients recruited from hospital
dermatology outpatients clinics (Balci et al., 2009; Gisondi
et al., 2009; Soy et al., 2009; El-Mongy et al., 2010; Enany
et al., 2011; Yiu et al., 2011) and dermatology inpatients with
relatively severe disease (Boehncke et al., 2007; Ludwig et al.,
2007). These factors could explain the discrepancy between
the elevated measures of atherosclerosis in psoriasis patients
compared with the controls in these studies and the absence
of a significant difference in our study. The mean values for
IMT in the Rotterdam Study are in the range of the mean IMT
among psoriasis outpatients without cardiovascular risk factors
or history of CVD in two studies (El-Mongy et al., 2010; Enany
et al., 2011). The control groups in these studies were much
smaller, consisted of healthy individuals, and had significantly
lower IMT values compared with the psoriasis group. The IMT
studies and the only two other studies measuring PWV
(Gisondi et al., 2009; Soy et al., 2009) included patients
who were 20 years younger on average than the Rotterdam
Study population, possibly explaining the lower IMT and PWV
values obtained.
Only one other study analyzed the CAC score in 32 patients
with a long history of severe psoriasis, showing a higher mean
CAC score (78±140) than in the Rotterdam Study, but with a
CAC score range similar to our study. The controls, matched
for cardiovascular risk factors, had a considerably lower CAC
score than psoriasis patients, possibly because they were
enrolled from a different source (Ludwig et al., 2007).
Coronary heart disease
Our results, based on hard end points of MI and CHD
mortality, are in line with studies confirming the absence of
association between psoriasis and MI (Brauchli et al., 2009;
Schmitt and Ford, 2010; Wakkee et al., 2010; Shapiro et al.,
2012). A German case–control study showed that psoriasis
was associated with cardiovascular risk factors, but not
with MI and stroke, with odds ratios (ORs) of 1.14 (95% CI
0.81–1.62) and 0.97 (95% CI 0.61–1.54), respectively (Schmitt
Table 3. Psoriasis and risk of cardiovascular disease and its components
Total psoriasis N¼259 Mild psoriasis N¼197 Moderate to severe psoriasis N¼ 62
Event HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Cardiovascular diseasea
Npso¼ 28 Nref¼1,585
Crude 0.69 (0.48–1.00) 0.05 0.85 (0.57–1.29) 0.45 0.37 (0.15–0.89) 0.03
Age and gender adjusted 0.83 (0.57–1.21) 0.15 0.98 (0.65–1.48) 0.92 0.49 (0.21–1.19) 0.11
Fully adjustedb 0.73 (0.50–1.06) 0.10 0.84 (0.56–1.27) 0.41 0.46 (0.19–1.10) 0.08
Coronary heart disease
Npso¼ 14 Nref¼812
Crude 0.69 (0.40–1.16) 0.16 0.94 (0.54–1.62) 0.81 0.15 (0.02–1.08) 0.06
Age and gender adjusted 0.80 (0.47–1.36) 0.41 1.02 (0.59–1.76) 0.96 0.21 (0.03–1.50) 0.12
Fully adjustedb 0.70 (0.41–1.19) 0.18 0.85 (0.49–1.47) 0.56 0.21 (0.03–1.50) 0.12
Cerebral infarction
Npso¼ 9 Nref¼ 467
Crude 0.73 (0.37–1.42) 0.36 0.69 (0.31–1.55) 0.37 0.82 (0.27–2.56) 0.74
Age and gender adjusted 0.79 (0.41–1.52) 0.48 0.71 (0.32–1.59) 0.41 1.01 (0.32–3.13) 0.99
Fully adjustedb 0.69 (0.36–1.34) 0.28 0.62 (0.28–1.38) 0.24 0.93 (0.30–2.90) 0.90
Heart failure
Npso¼ 20 Nref¼1,091
Crude 0.74 (0.47–1.15) 0.17 1.02 (0.65–1.60) 0.94 0.12 (0.02–0.83) 0.03
Age and gender adjusted 0.91 (0.58–1.41) 0.67 1.17 (0.74–1.84) 0.50 0.17 (0.02–1.22) 0.08
Fully adjustedb 0.80 (0.51–1.25) 0.33 1.01 (0.64–1.59) 0.97 0.16 (0.02–1.15) 0.07
Abbreviations: CI, confidence interval; HR, hazard ratio; Npso and Nref, number of events in psoriasis and reference group, respectively.
N psoriasis¼259, N reference¼ 7,931. All HRs were calculated using time-dependent Cox regression with psoriasis as the time-dependent variable using the
index date.
aCardiovascular disease includes coronary heart disease, cerebral infarction confirmed by computed tomography, and heart failure.
bAdjusted for age, gender, current smoking, body mass index, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, antihypertensive
medication, and diabetes mellitus.
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and Ford, 2010). A large Dutch cohort demonstrated that the
adjusted risk of ischemic heart disease was comparable
between the psoriasis and reference cohort (HR 1.05, 95%
CI 0.95–1.17) (Wakkee et al., 2010). Another case–control
study among Israeli inpatients showed that the association
between CVD and psoriasis was no longer significant after
adjusting for risk factors (Shapiro et al., 2012). In the PUVA
follow-up study, psoriasis patients were not at an increased
risk of CVD deaths (standardized mortality ratio 1.02, 95%
CI 0.90–1.60), with the exception of patients with extremely
severe disease (Stern and Huibregtse, 2011).
Of more than 20 original studies on the association between
MI, CHD, and psoriasis, the majority were based on secondary
databases, limited by detection bias and where information
on cardiovascular confounders was not always available.
Although most studies have demonstrated increased, but
varying, risks of cardiovascular events, a recent systematic
review concluded that there was no consistency in the
literature as to elevated cardiovascular risk factors in psoriasis
patients (Prey et al., 2010). Even the studies investigating these
outcomes using the same database (GPRD) resulted in varying
risks owing to differences in study design, exposure, and
outcome definitions, and depending on whether incident or
prevalent cases of CVD were investigated (Gelfand et al.,
2006; Kaye et al., 2008; Brauchli et al., 2009; Mehta et al.,
2010; Leening et al., 2012). Initially, all psoriasis patients
seemed to be at an increased risk of developing CVD, but now
it is considered to be limited to young patients with severe
disease (Gelfand et al., 2006; Brauchli et al., 2009; Ahlehoff
et al., 2011a; Ahlehoff et al., 2011b; Li et al., 2012).
Interestingly, in our study, the risk estimates obtained for
CVD in psoriasis patients, albeit not statistically significant,
were consistently below one, suggesting a possible protective
effect for which we have no explanation.
Stroke
The risk of stroke in psoriasis has been investigated in several
studies, but with different outcome definitions: ischemic,
hemorrhagic, unspecified stroke, stroke confirmed or not
by computed tomography (CT) to including all subtypes.
In studies assessing CVD, stroke should be restricted to ischemic
stroke excluding non-cardiovascular-related subtypes in order
to avoid overestimation of cardiovascular events. The impact
of this outcome definition is well illustrated in two publica-
tions using the Taiwanese Health Insurance database: in one
study psoriasis is not associated with stroke (OR 1.04, 95% CI
0.82–1.33) (Yang et al., 2011), and in another study psoriasis
is associated with ischemic stroke (HR 1.27, 95% CI 1.05–
1.52) (Chiang et al., 2012). A Danish population-based study
showed that the adjusted risk for ischemic stroke was
significantly higher in mild and severe psoriasis patients
compared with the reference population (Ahlehoff et al.,
2011b). The disparity with our results may be explained by
the difference in the degree of adjustment for cardiovascular
risk factors, measuring study outcomes independent of
patients’ health status, the use of a narrow definition of
stroke, and assessment of incident versus prevalent stroke
(Kaye et al., 2008; Gelfand et al., 2009).
Heart failure
Only one other study analyzed heart failure using data from
the Taiwan National Health Insurance, adjusting for income,
geographical region, and level of urbanization of the patients’
community, with an OR for psoriasis of 1.63 (95% CI 1.22–2.19)
(Yang et al., 2011). In this same study, mild psoriasis patients
did not have an elevated risk for heart failure; however,
a significant association was found with psoriasis patients
exposed to phototherapy or systemic therapy (OR 1.69, 95%
CI 1.24–2.30). The discrepancy with our results can be
explained by missing adjustment for cardiovascular risk
factors.
Strengths and limitations
The Rotterdam Study is a detailed population-based study with
a follow-up of more than 10 years and a very high participa-
tion rate among the inhabitants of the same district in
Rotterdam (Hofman et al., 2011). Psoriasis subjects under-
went the same examinations as the reference population every
4 years, irrespective of disease severity, health status, and
overall health-care utilization, minimizing selection and
detection bias. Epidemiology of CVD being one of the main
study objectives of the Rotterdam Study, this therefore reduces
residual confounding on cardiovascular predictors and disease.
In this study, the standardized measures of atherosclerosis are
state-of-the-art, and the identification of cardiovascular events
(using clinical data, symptoms, electrocardiogram changes,
echocardiography, X-rays, CT, diagnoses by medical spe-
cialists and not only ICD codes (Leening et al., 2012)) limits
possible nondifferential misclassification bias. The present
study used hard end points, such as hard CHD and
CT-confirmed stroke, to minimize the effect of overdetection
of softer end points, such as angina or transient ischemic
attack, and therefore the outcomes are less likely to be
affected by subject status or psoriatic disease. Psoriasis
patients were identified using medical files, pharmacy data,
and, in a subset, clinical examinations, resulting in the
expected prevalence of 3% (of which 24% had moderate
to severe disease), confirming the validity of the exposure
definition (Nijsten et al., 2007; Kurd and Gelfand, 2009).
For all psoriasis patients, a reliable date of onset of
disease was available. To explore the cause–effect relation-
ship of whether chronic psoriasis-related inflammation
would lead to atherosclerosis and CVD, we restricted
the analyses to measurements and events occurring after
psoriasis onset during an observation period of more than
10 years.
Subjects were only included in the Rotterdam Study if they
were 55 years and older. This limits the generalizability of our
findings to younger or non-Caucasian populations. In the
studies that document increased risk of CVD, the greatest
relative risk is in the younger population with severe disease;
however, because of the design of the Rotterdam Study, we
were unable to investigate this risk in younger patients.
Moreover, the majority of the patients in our study had mild
disease. We acknowledge the limited sample size of the
psoriasis group; however, this is inherent to a population-
based approach. We found no significant difference in risk of
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CVD between psoriasis and reference subjects. Although
our study may have been underpowered for some of the end
points, a larger sample size would most likely lead to a
narrower 95% CI but not alter the HR substantially. More-
over, for the subclinical measures of atherosclerosis, post
hoc power analyses showed that our study had very high
power to show a difference between the two groups (data
not shown). The case definition of psoriasis may have
resulted in the identification of false-positive psoriasis cases,
which could have diluted the effect of psoriasis on CVD,
resulting in risk estimates closer to one (i.e., differential
misclassification bias). This is the largest study to concur-
rently assess subclinical atherosclerosis and incident cardi-
ovascular events adjusting for cardiovascular risk factors in
the same population-based sample of psoriasis patients and
reference subjects. The case definition of psoriasis was
predominantly based on health-care utilization (i.e., diagnoses
by physicians and drug dispenses), not taking into account
patients who had not sought care for their psoriasis. These
would have most probably been mild psoriasis cases, and we
expect that including them would not have influenced our
results considerably. In order to capture the entire range of
psoriasis patients in the future, screening for skin conditions in
Rotterdam Study participants is ongoing, independent of
whether participants seek medical care from their GP or take
antipsoriatic medication.
Conclusion
Psoriasis patients from the general population with pre-
dominantly mild disease have a comparable cardiovascular
risk profile to subjects without psoriasis, and do not have a
higher prevalence of subclinical atherosclerosis. In the
present cohort, psoriasis did not appear to be an indepen-
dent risk factor for incident cardiovascular events.
Ultimately, a prospective cohort of incident psoriasis cases
of substantial size, varying in age and disease severity, could
clarify the relationship between psoriasis, atherosclerosis,
and CVD.
MATERIALS AND METHODS
Study population
This study is embedded within the prospective population-based
Rotterdam Study, described elsewhere (Hofman et al., 2011). All
inhabitants of a suburb of Rotterdam aged 45 years and older were
invited to participate. The baseline examination was completed
between 1990 and 1993. In 2000, the cohort was extended to
include inhabitants who reached the age of 55 years or migrated to
the research area. In 2005, a second expansion included all persons
aged 45 years and older. Participants have been followed up since
inclusion, and examined every 4 years. The current study using
data from the original and first extended cohort comprised 10,994
subjects (participation rate of 75%). Information on non-participants
was not available because they had not consented to participate in
the study.
The Rotterdam Study was approved by the Medical Ethics
Committee of Erasmus University, Rotterdam, the Netherlands, and
adhered to the Helsinki Guidelines. All participants gave written
informed consent.
Assessment of psoriasis
Psoriasis subjects in the Rotterdam Study were identified on a
continuous basis. Medical record review was performed after a digital
search for subjects with a diagnostic code for psoriasis by the
GP (S91) and for participants with psoriasis medication according
to the Anatomical Therapeutic Chemical Classification System
(WHO, 1999). The GP records were searched for the diagnosis of
psoriasis in the GP notes, medical specialist reports, and hospital
discharge letters, registering the medical provider who diagnosed
psoriasis. Patients were defined as having ‘‘possible’’ psoriasis if they
had a prescription for one of the following medications: psoralens,
dithranol, calcipotriol, calcitriol, coal tar, tacrolimus, pimecrolimus,
fumaric acid, acitretin, methotrexate, ciclosporin, or biologicals.
Definite psoriasis cases (n¼ 277) were patients with a diagnosis of
psoriasis by a dermatologist or rheumatologist, patients whose disease
was mentioned twice or more by the GP, patients with a diagnosis of
psoriasis based on psoriasis-specific medication, and patients with
psoriasis at the time of skin examination (Supplementary Figure S1
online). The latter was available in a subgroup of 1,551 of the 10,994
subjects who were screened for dermatological conditions between
August 2010 and November 2011. For psoriasis patients from this
group (n¼ 47), the date of onset and Psoriasis Area and Severity Index
(PASI) were recorded. The PASI was available in 14% of patients, and
ranged from 0.4–12.7.
We validated our algorithm using skin examination conducted in
1,551 subjects as the golden standard. The sensitivity and specificity
were both 98%, with a positive predictive value of 62% and negative
predictive value of 99.9%. Accounting for patients who did not have
psoriasis at skin examination, but during the interview reported
having red, scaly plaques in the past, yielded a positive predictive
value of 82%.
The date of psoriasis onset was the date of first diagnosis in the
medical record (by the dermatologist, other medical specialist, or the
GP), the date of first antipsoriatic medication, or the self-reported date
of onset (n¼ 18), whichever came first. For the analyses, the ‘‘index
date’’ for psoriasis was determined on the basis of the date of psoriasis
onset: this was the study entrance date for prevalent cases (with
psoriasis onset before study inclusion) or a later date corresponding to
the date of psoriasis onset for patients who developed psoriasis after
inclusion to the study.
Patients had mild psoriasis if they had only used topical treatment,
had a PASIo10 at skin examination, or if they had not been treated at
all during follow-up. Patients with moderate to severe disease had
been treated with UV therapy or systemic medication during follow-
up (Gelfand et al., 2006; Wakkee et al., 2010) or had a PASI410.
Reference population
The reference population consisted of 9,023 participants in the
Rotterdam Study who did not use any of the above-mentioned anti-
psoriatic medications during the follow-up and did not have a GP code
for psoriasis. Their ‘‘index date’’ was the date of inclusion in the study.
Subclinical measures of atherosclerosis
Atherosclerosis measurements were repeated at center visits. For
psoriasis patients, the first available measurement after the date of
onset was used in our analyses. If this was not available, measure-
ments up to 6 months before the date of onset were included, and
otherwise psoriasis patients were excluded from the analyses. For
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reference subjects, the first available measurements after inclusion in
the study were used. Carotid artherosclerosis and lower-extremity
atherosclerosis were assessed by measuring carotid IMT and plaques
and ABI. Peripheral artery disease was defined as ABI values of 0.9 or
less (Mohler, 2003). CAC was assessed in the epicardial coronary
arteries on CT scans. Carotid–femoral PWV measured aortic stiffness.
The methods for these measurements are described in Supplementary
Material and Methods, and Supplementary Figure S2 online depicts
when they were performed. The measurements were not available
for the entire population because of various reasons: no consent
obtained, measurements conducted after patients left follow-up, and
limited availability of ultrasonographers. In addition, for psoriasis
patients, we only included measures of atherosclerosis after psoriasis
onset in our analyses.
Cardiovascular outcomes
The clinical outcomes of this study are incident cardiovascular
morbidity and mortality, described in detail previously (Leening
et al., 2012). The medical records of all study participants were
continuously assessed for events. In brief, we investigated incident
‘‘hard’’ CHD defined as MI (fatal or non-fatal) and fatal CHD,
excluding subjects with a history of MI or revascularization
(Vliegenthart et al., 2005). Stroke was defined as cerebral infarction
diagnosed by CT scan, excluding stroke by intracerebral hemorrhage,
possibly caused by trauma and therefore not a cardiovascular event
(Hollander et al., 2003; Wieberdink et al., 2012). Heart failure was
defined according to the European Society of Cardiology (Swedberg
et al., 2005). Methods on assignment of prevalent and incident heart
failure cases in the Rotterdam Study have been elaborated elsewhere
(Mosterd et al., 1999; Bleumink et al., 2004).
The primary outcome was incident CVD; the secondary outcomes
were the components of CVD, namely CHD, cerebral infarction
diagnosed by CT, and heart failure. Median (interquartile range) for
follow-up was 9.11 (7.55, 16.03) years.
Cardiovascular risk factors
Information on traditional cardiovascular risk factors was collected:
age, gender, smoking, BMI, total and high-density lipoprotein
cholesterol, systolic and diastolic blood pressure, use of lipid-lowering
drugs, diabetes mellitus defined as the use of oral blood-glucose-
lowering drugs or insulin, or non-fasting glucose 411 mmol l 1 or
fasting glucose 47 mmol l 1. Hypertension was defined as systolic
pressureX140 mm Hg or diastolic pressureX90 mm Hg (mean of two
measurements) or the use of blood pressure–lowering medication for
the indication of hypertension (Hofman et al., 2011).
Statistical analysis
The distribution of baseline characteristics was compared using t-test
for continuous variables and w2 test for proportions. For atherosclero-
sis, we compared crude and adjusted means (±SD) for IMT, ABI, and
PWV, and proportions for peripheral artery disease and carotid
plaques across the groups using general linear model analysis of
variance. Two adjusted models were performed: one for age and
gender, and the second model adjusting additionally for BMI, systolic
blood pressure, treatment of hypertension, total and high-density
lipoprotein cholesterol, current smoking, and diabetes mellitus
(Wilson et al., 1998; D’Agostino et al., 2008). Because of the
skewed distribution of CAC and to handle CAC scores of zero,
we used the natural logarithm of (CACþ 1) and back-transformed the
results to obtain the geometric mean (95% CI). We calculated crude
and adjusted HR (95% CI) for developing incident CHD, stroke, and
heart failure using a time-dependent Cox regression analysis where
psoriasis was treated as a time-dependent variable using the index
date. In this analysis, the follow-up in years started from the date of
inclusion to the Rotterdam Study until the first cardiovascular event,
until death, or the end of the follow-up period predetermined for the
analyses, whichever came first. We adjusted these analyses according
to the two above-mentioned models.
For all analyses, subjects with more than four missing covariates
were excluded. For subjects with less than four missing values, the
covariates were imputed using multiple imputation (maximum
missing values were 2.8%, for BMI).
Sensitivity analysis
To assess the impact of psoriasis severity, the analyses were repeated
for patients with mild and moderate to severe disease. In a Cox
regression analysis, we investigated whether patients with psoriasis
onset before study inclusion (and therefore a longer duration of
psoriasis) had an increased risk of CVD.
All analyses were conducted with SPSS version 17.0. (SPSS,
Chicago, IL).
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